Navigation Links
Mount Sinai researchers say new strain of bird flu packs a punch even after becoming drug-resistant
Date:12/11/2013

NEW YORK, NY - December 10, 2013 Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza the virus that causes the flu appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications.

It is not uncommon for influenza viruses to develop genetic mutations that make them less susceptible to anti-flu drugs. However, these mutations usually come at a cost to the virus, weakening its ability to replicate and to spread from one person to another.

Initial reports suggested that H7N9, an avian strain of influenza A that emerged in China last spring, could rapidly develop a mutation that made it resistant to treatment with the antiviral medication Tamiflu (oseltamivir). However, patients in whom drug resistance developed often had prolonged, severe infections and poor clinical outcomes. No vaccine is currently available to prevent H7N9, which infected at least 135 people and caused 44 deaths during the outbreak. In the absence of a vaccine, antiviral drugs are the only means of defense for patients who are infected with new strains of the flu.

"In this outbreak, we saw some differences in the behavior of H7N9 and other avian influenza strains that can infect humans, beginning with the rapid development of antiviral resistance in some people who were treated with oseltamivir and the persistence of high viral loads in those patients," said lead investigator Nicole Bouvier, MD, Assistant Professor of Medicine, Infectious Diseases at the Icahn School of Medicine at Mount Sinai.

Specifically, the investigators found that a drug-resistant H7N9 virus retained its ability to replicate in human respiratory cells and was comparable to a non-resistant form of the virus in producing severe illness in animal models. And although H7N9 appears to have a limited ability to spread readily from human to human, transmissibility in animal models was comparable between drug-susceptible and drug-resistant strains. "Transmission was inefficient for both of the H7N9 viruses that we tested in our experiments," said Dr. Bouvier. "But surprisingly, transmission of the drug-resistant virus was no less efficient than that of the drug-sensitive version."

"Many of the people infected with H7N9 during the outbreak in China were elderly or had other conditions that predisposed them to severe influenza illness," observed Dr. Bouvier. "Nevertheless, our study suggests that flu viruses can indeed develop drug-resistant mutations without suffering a penalty in terms of their own fitness."

Older antiviral drugs such as amantadine are no longer effective in treating most strains of the flu that infect humans. Newer antiviral drugs called neuraminidase inhibitors block an enzyme that helps the virus replicate. These drugs include Tamiflu, a pill, and Relenza (zanamivir), a powder that is inhaled. Both medications have drawbacks: flu viruses can develop resistance to the medications in people who take them, and, in many parts of the world, neither drug is available in an intravenous form to treat those with severe infections.

"Our study underscores the need to develop a bigger arsenal of antiviral drugs and vaccines, which will allow us to outsmart the influenza virus," said Dr. Bouvier. "Researchers at Mount Sinai are actively engaged in identifying new targets for drug therapy and are working to develop a universal vaccine that will prevent multiple strains of influenza."


'/>"/>

Contact: Sid Dinsay
sid.dinsay@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. UNH research adds to mounting evidence against popular pavement sealcoat
2. Expedition to undersea mountain yields new information about sub-seafloor structure
3. CU research shows warming climate threatens ecology at mountain research site west of Boulder
4. Accelerating climate change exerts strong pressure on Europes mountain flora
5. Global warming has driven Europes mountain plants to migrate 2.7 meters upwards in 7 years
6. European mountain plant population shows delayed response to climate change
7. Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctors Offices.
8. Nitrogen pollution changing Rocky Mountain National Park vegetation, says CU-Boulder-led study
9. NCEAS DataONE streamlines search and analysis of massive amounts of ecological data
10. Mount Sinai researchers solve mystery surrounding the death of two sisters nearly 50 years ago
11. IdentiSys acquires the Identification, Security and Presentation Divisions of Mountainland Business Systems, a Utah based reseller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2016)... 13, 2016 --> ... new market report titled - Biometric Sensors Market - Global ... - 2023. According to the report, the global biometric sensors market was ... to reach US$1,625.8 mn by 2023, expanding at a ... of volume, the biometric sensors market is expected to ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 /PRNewswire/ ... sensor-based diagnostic products, today announced the closing of a $9 ... investors.  Proceeds from the financing will be used to accelerate ... device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has been ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused ... announced that it will present at the 18 th ... February 8, 2016 at 10:00 a.m. EST in ... , DelMar,s president and CEO, will provide an update on ...
(Date:2/4/2016)... BEIJING , Feb. 4, 2016 Sinovac ... ), a leading provider of biopharmaceutical products in ... committee of its board of directors received on February ... 3, 2016, from a consortium comprised of PKU V-Ming ... Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development ( ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
Breaking Biology Technology: